L’anticoagulation dans la fibrillation atriale du sujet âgé : point de vue du gériatre avec un focus sur les anticoagulants oraux directs

Hanon, 2013, Expert consensus of the French society of geriatrics and gerontology and the French society of cardiology on the management of atrial fibrillation in elderly people, Geriatr Psychol Neuropsychiatr Vieil, 11, 117 Chugh, 2001, Epidemiology and natural history of atrial fibrillation: clinical implications, Am Coll Cardiol, 37, 371, 10.1016/S0735-1097(00)01107-4 Charlemagne, 2011, Epidemiology of atrial fibrillation in France: extrapolation of international epidemiological data to France and analysis of French hospitalization data, Arch Cardiovasc Dis, 104, 115, 10.1016/j.acvd.2010.11.012 Leys, 2005, Poststroke dementia, Lancet Neurol, 4, 752, 10.1016/S1474-4422(05)70221-0 Dulli, 2003, Atrial fibrillation is associated with severe acute ischemic stroke, Neuroepidemiology, 22, 118, 10.1159/000068743 Slot, 2008, Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies, BMJ, 336, 376, 10.1136/bmj.39456.688333.BE Emelia, 1998, Impact of atrial fibrillation on the risk of death. The Framingham Heart Study, Circulation, 98, 946, 10.1161/01.CIR.98.10.946 Saxena, 2001, Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial, Stroke, 32, 2333, 10.1161/hs1001.097093 Thacker, 2013, Atrial fibrillation and cognitive decline: a longitudinal cohort study, Neurology, 81, 119, 10.1212/WNL.0b013e31829a33d1 Udompanich, 2013, Atrial fibrillation as a risk factor for cognitive impairment: a semi-systematic review, QJM, 106, 795, 10.1093/qjmed/hct129 Camm, 2012, 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association, Eur Heart J, 33, 2719, 10.1093/eurheartj/ehs253 Chen, 2013, CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis, J Geriatr Cardiol, 10, 258 Gage, 2006, Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation, Am Heart J, 15, 713, 10.1016/j.ahj.2005.04.017 Singer, 2013, A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score, J Am Heart Assoc, 2, e000250, 10.1161/JAHA.113.000250 Apostolakis, 2012, J Am Coll Cardiol, 60, 861, 10.1016/j.jacc.2012.06.019 Bauersachs, 2012, Use of anticoagulants in elderly patients, Thromb Res, 129, 107, 10.1016/j.thromres.2011.09.013 Palaniswamy, 2011, Association of warfarin use with valvular and vascular calcification: a review, Clin Cardiol, 34, 74, 10.1002/clc.20865 Zhang, 2014, Research progress of warfarin-associated vascular calcification and its possible therapy, J Cardiovasc Pharmacol, 63, 76, 10.1097/FJC.0000000000000008 Fung, 2012, Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin, Semin Thromb Hemost, 38, 893, 10.1055/s-0032-1328891 Hart, 1999, Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis, Ann Intern Med, 131, 492, 10.7326/0003-4819-131-7-199910050-00003 Singer, 2009, The net clinical benefit of warfarin anticoagulation in atrial fibrillation, Ann Intern Med, 151, 297, 10.7326/0003-4819-151-5-200909010-00003 Hart, 2007, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Ann Intern Med, 146, 857, 10.7326/0003-4819-146-12-200706190-00007 Lang, 2009, STOPP-START: adaptation of a French language screening tool for detecting inappropriate prescriptions in older people, Can J Public Health, 100, 426, 10.1007/BF03404338 Steinberg, 2013, Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the ORBIT-AF Registry, Circulation, 128, 721, 10.1161/CIRCULATIONAHA.113.002927 Agence nationale de sécurité du médicament et des produits de santé (ANSM), 2014 Pouyanne, 2000, Admissions to hospital caused by adverse drug reactions: cross-sectional incidence study. French pharmacovigilance centres, BMJ, 320, 103, 10.1136/bmj.320.7241.1036 Vogel, 2008, Prospective study of oral anticoagulation control in 110 very elderly hospitalized patients and of risk factors for poor control, Presse Med, 37, 1723, 10.1016/j.lpm.2008.04.005 Cambus, 2013, [Anticoagulant clinics are they effective in France? Performance evaluation of six anticoagulant clinics concerning the management of vitamin K antagonists], Rev Med Interne, 34, 515, 10.1016/j.revmed.2013.02.001 Mahé, 2013, [Anticoagulant clinics in France? Which usefulness now and for the future?], Rev Med Interne, 34, 513, 10.1016/j.revmed.2013.02.033 Eikelboom, 2013, Dabigatran versus warfarin in patients with mechanical heart valves, N Engl J Med, 26, 1206, 10.1056/NEJMoa1300615 Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, N Engl J Med, 361, 1139, 10.1056/NEJMoa0905561 Uchino, 2012, Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials, Arch Intern Med, 172, 397, 10.1001/archinternmed.2011.1666 Eikelboom, 2011, Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial, Circulation, 123, 2363, 10.1161/CIRCULATIONAHA.110.004747 Connolly, 2013, The long-term multicenter observational study of dabigatran treatment in patients with Atrial Fibrillation (RELY-ABLE) Study, Circulation, 128, 237, 10.1161/CIRCULATIONAHA.112.001139 Patel, 2011, Rivaroxaban versus warfarin in non-valvular atrial fibrillation, N Engl J Med, 365, 883, 10.1056/NEJMoa1009638 Goodman, 2014, Factors associated with major bleeding events: insights from the Rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF), J Am Coll Cardiol, 63, 891, 10.1016/j.jacc.2013.11.013 Granger, 2011, Apixaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 365, 981, 10.1056/NEJMoa1107039 Giugliano, 2013, Edoxaban versus warfarin in patients with atrial fibrillation, N Engl J Med, 369, 2093, 10.1056/NEJMoa1310907 Chatterjee, 2013, New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation, JAMA Neurol, 70, 1486 Holster, 2013, New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis, Gastroenterology, 145, 105, 10.1053/j.gastro.2013.02.041 Ruff, 2014, Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet, 383, 955, 10.1016/S0140-6736(13)62343-0 Banerjee, 2012, Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study, Thromb Haemost, 107, 584, 10.1160/TH11-11-0784 Lang, 2010, What do we learn from the SAFEs cohort to fit hospital care models for aged inpatient?, Presse Med, 39, 1132, 10.1016/j.lpm.2010.05.009 Lafuente-Lafuente, 2013, Anticoagulation of older people: what is new?, Press Med, 42, 187, 10.1016/j.lpm.2012.05.031 Haute Autorité de santé (HAS), 2014 Makris, 2010, Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient, J Thromb Thrombolysis, 29, 171, 10.1007/s11239-009-0412-5 Deedwania, 2013, New oral anticoagulants in elderly patients with atrial fibrillation, Am J Med, 126, 289, 10.1016/j.amjmed.2012.10.012 Stangier, 2008, Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects, Clin Parmacokinet, 47, 47, 10.2165/00003088-200847010-00005 Okada, 2012, Exfoliative esophagitis and esophageal ulcer induced by dabigatran, K Endoscopy, 44, E23 Ootani, 2014, Dabigatran-induced esophagitis, Clin Gastroenterol Hepatol, 12, e55, 10.1016/j.cgh.2013.09.010